【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.

智通财经06-03

【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司自主研发的注射用重组人促甲状腺激素(rhTSH)向国家药品监督管理局(NMPA)递交了生物制品上市许可申请(BLA)，目前等待正式受理中。本次递交新药上市申请的适应症是用于既往接受过甲状腺切除术的分化型甲状腺癌患者随访时的放射性碘(131I)全身显像...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2440902456?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-03 16:11","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2440902456","market":"us","top_or_hot":-1,"title":"【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.","media":"智通财经","content":"<div>\n<p>【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司自主研发的注射用重组人促甲状腺激素(rhTSH)向国家药品监督管理局(NMPA)递交了生物制品上市许可申请(BLA)，目前等待正式受理中。本次递交新药上市申请的适应症是用于既往接受过甲状腺切除术的分化型甲状腺癌患者随访时的放射性碘(131I)全身显像...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=astock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-03 16:11 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=astock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司自主研发的注射用重组人促甲状腺激素(rhTSH)向国家药品监督管理局(NMPA)递交了生物制品上市许可申请(BLA)，目前等待正式受理中。本次递交新药上市申请的适应症是用于既往接受过甲状腺切除术的分化型甲状腺癌患者随访时的放射性碘(131I)全身显像...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=astock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","article_id":"2440902456","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440902456","pubTimestamp":1717402292,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司自主研发的注射用重组人促甲状腺激素(rhTSH)向","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688266":"泽璟制药","BK4211":"区域性银行","WBS":"韦伯斯特金融","BK0239":"医药制造","BLA.AU":"Blue Sky Alternative Inv"},"translate_title":"[Zejing Pharmaceutical (688266. SH) submitted an application for marketing authorization of recombinant human thyroid-stimulating hormone biological products for injection] Zhitong Finance APP News, Zejing Pharmaceutical (688266.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1,"BLA.AU":1,"WBS":1},"content_text":"【泽璟制药(688266.SH)递交注射用重组人促甲状腺激素生物制品上市许可申请】智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司自主研发的注射用重组人促甲状腺激素(rhTSH)向国家药品监督管理局(NMPA)递交了生物制品上市许可申请(BLA)，目前等待正式受理中。本次递交新药上市申请的适应症是用于既往接受过甲状腺切除术的分化型甲状腺癌患者随访时的放射性碘(131I)全身显像(WBS)检查和血清甲状腺球蛋白(Tg)检测。截至目前，国内尚未有重组人促甲状腺激素获批用于该项适应症。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440902456"}